Experts discuss the challenges of treating wet age-related macular degeneration (AMD) with current anti-VEGF therapies and emphasize the need for more durable treatment options. The conversation highlights the potential for advancements that could significantly improve patient outcomes.

EyePoint's pivotal study for its wet AMD drug did not meet its primary endpoint, yet the company and analysts believe there remains a potential pathway to approval. This outcome may challenge investor confidence moving forward.

EyePoint's Phase 3 trial for a treatment aimed at reducing the burden of age-related macular degeneration has failed, resulting in a 70% drop in stock value. This setback highlights the competitive landscape in the AMD treatment space.

Curative Biotechnology has engaged Sterling Pharmaceutical Services to manufacture clinical supplies for its metformin-based topical ophthalmic therapy aimed at treating intermediate and late-stage Age-Related Macular Degeneration (AMD). The company is preparing for a first-in-human clinical trial under a Cooperative Research and Development Agreement with the National Eye Institute.

Research identifies a siRNA targeting S6K1 that reveals photoreceptor phospholipid metabolism as a contributor to lipid buildup in age-related macular degeneration. This discovery could inform future therapeutic strategies for managing the disease.